CSL Behring to Donate 10 Million IUs of its Bleeding Disorder
Protein Therapies and to Contribute More than $1.1 Million in Financial Support to WFH
MONTREAL and KING OF PRUSSIA, Pa., April 14, 2015 /PRNewswire/ -- In
recognition of World Hemophilia Day April
17, the World Federation of Hemophilia (WFH) and CSL Behring
announced today that CSL Behring has once again committed to
donating bleeding disorder protein therapy international units
(IUs) to the WFH Global Alliance for Progress (GAP) Program and
other WFH programs, as well as making significant financial
contributions to WFH.
As part of the new agreement, CSL Behring will provide 10
million IUs of one or more of its products from its broad portfolio
of bleeding disorder protein therapies to the WFH over the period
of three years, beginning in 2016. The GAP Program strives to
improve the diagnosis and treatment of bleeding disorders in
developing countries. In 2009, CSL was the first biotherapies
company in the world to make a multiyear commitment to WFH to aid
the GAP Program with humanitarian aid coagulation factor donations
over an extended period of time. CSL Behring will also provide more
than $1.1 million in financial
support to WFH's Corporate Partner and GAP programs over the three
year period. World Hemophilia Day is promoted by WFH to increase
global awareness of hemophilia and other inherited bleeding
disorders.
"WFH established the GAP Program to advance our vision of
Treatment for All, working to improve diagnosis and access to care
for the millions of people who have a rare bleeding disorder yet
remain without treatment," said WFH President Alain Weill. "CSL Behring shares WFH's vision in
improving diagnosis and treatment access. We are once again
grateful for the generous pledge made by CSL Behring as we strive
to help fulfill our commitment to introduce clotting factor
concentrates in developing countries where people who are living
with a bleeding disorder may not be able to access appropriate
treatment."
Since its first donation in 2009, CSL Behring has provided
nearly 14 million IUs of its bleeding disorder protein therapies to
treat people with hemophilia or von Willebrand disease (VWD) in
developing countries.
"CSL Behring has long been at the forefront of enabling people
with serious conditions to lead normal and healthy lives," said
Paul Perreault, CEO and Managing
Director of CSL Limited. "The GAP Program aligns with CSL Behring's
goal to make meaningful differences in the lives of people who are
living with serious diseases, such as hemophilia or von Willebrand
disease. We look forward to our continued partnership with
WFH as we work together to improve treatment access in developing
countries around the world."
About the Global Alliance for Progress Program
The Global Alliance for Progress (GAP) Program is a healthcare
development project launched in 2003, now in its Second Decade
phase (2013-2022). The overarching goals for the GAP Program will
be to increase by 50,000 the worldwide number of people
identified/diagnosed with a bleeding disorder, as well as to ensure
that 50 percent of those newly diagnosed are from the world's most
impoverished countries. CSL Behring supports the WFH GAP Program as
one of the program sponsors.
About the World Federation of Hemophilia
For over 50 years, the World Federation of Hemophilia (WFH), an
international not-for-profit organization, has worked to improve
the lives of people with hemophilia and other inherited bleeding
disorders. Established in 1963, it is a global network of patient
organizations in 127 countries and has official recognition from
the World Health Organization. Visit WFH online at www.wfh.org
About CSL Behring
CSL Behring is a leader in the
plasma protein therapeutics industry. Committed to saving lives and
improving the quality of life for people with rare and serious
diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat
coagulation disorders including hemophilia and von Willebrand
disease, primary immune deficiencies, hereditary angioedema and
inherited respiratory disease, and neurological disorders in
certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent
hemolytic disease of the newborn.
CSL Behring operates one of the world's largest plasma
collection networks, CSL Plasma. CSL Behring is a global
biopharmaceutical company and a member of the CSL Group of
companies. The parent company, CSL Limited (ASX:CSL), is
headquartered in Melbourne,
Australia. For more information, visit
www.cslbehring.com.
Contact:
Sarah Ford
World Federation of Hemophilia
Office: 514-394-2822
sford@wfh.org
Greg Healy
CSL Behring
Office: 610-878-4841
Mobile: 610-906-4564
Greg.Healy@CSLBehring.com
Logo - http://photos.prnewswire.com/prnh/20150413/198241LOGO
Logo -
http://photos.prnewswire.com/prnh/20100914/PH63692LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/csl-behring-marks-world-hemophilia-day-by-renewing-pledge-to-world-federation-of-hemophilia-300065455.html
SOURCE CSL Behring; World Federation of Hemophilia